Avacta joint venture completes fresh funding round
(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Thursday that AffyXell, its joint venture with Daewoong Pharmaceuticals, has completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider preclinical pipeline of cell therapies.
Read more